Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCapital LeasesCash & Current InvestmentsCash & EquivalentsCommon EquityConstruction in ProgressCurrent AssetsCurrent Deferred RevenueCurrent LeasesFinished GoodsGoodwillGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityLong-Term Deferred TaxNon-Current AssetsOperating LeasesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPreferred Stock LiabilitiesPrepaid AssetsProperty, Plant & Equipment (Net)Property, Plant & Equipment (Net)Raw MaterialsReceivablesReceivables - NetRetained EarningsShareholder's EquityShares OutstandingShort-term InvestmentsTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current LiabilitiesTreasury SharesWork In Process
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Organogenesis Holdings (ORGO) Non-Current Assets (2016 - 2026)

Organogenesis Holdings has reported Non-Current Assets over the past 11 years, most recently at $236.5 million for Q4 2025.

  • For Q4 2025, Non-Current Assets rose 11.61% year-over-year to $236.5 million; the TTM value through Dec 2025 reached $846.8 million, down 1.54%, while the annual FY2025 figure was $236.5 million, 11.61% up from the prior year.
  • Non-Current Assets for Q4 2025 was $236.5 million at Organogenesis Holdings, up from $210.1 million in the prior quarter.
  • Over five years, Non-Current Assets peaked at $237.1 million in Q3 2023 and troughed at $133.9 million in Q1 2021.
  • A 5-year average of $210.1 million and a median of $217.4 million in 2021 define the central range for Non-Current Assets.
  • Biggest five-year swings in Non-Current Assets: surged 86.65% in 2021 and later dropped 13.87% in 2025.
  • Year by year, Non-Current Assets stood at $216.3 million in 2021, then rose by 4.84% to $226.8 million in 2022, then increased by 3.63% to $235.0 million in 2023, then decreased by 9.8% to $211.9 million in 2024, then grew by 11.61% to $236.5 million in 2025.
  • Business Quant data shows Non-Current Assets for ORGO at $236.5 million in Q4 2025, $210.1 million in Q3 2025, and $200.9 million in Q2 2025.